Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{184663,
        author = {JONA JOY and ALVINA CHRISTIANA B and NANDINI GOSWAMI and SHANILA THANKAM SURESH and ANIL DHAKAL},
        title = {PHARMACOTHERAPEUTIC CHALLENGES AND EVIDENCE GAPS IN DEVICE BASED HEART FAILURE THERAPY: A REVIEW OF OUTCOMES IN ICD AND LVAD POPULATIONS},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {12},
        number = {4},
        pages = {2854-2866},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=184663},
        abstract = {Device-based therapies have made great progress in treating heart failure with reduced ejection fraction (HFrEF). Examples of these therapies include implantable cardioverter-defibrillators (ICDs) and left ventricular assist devices (LVADs). These treatments increase survival and lower the chance of sudden cardiac death, but they do not lower the risk of complications such bleeding, infections, arrhythmias, and thromboembolic events. Despite the lack of trial evidence to guide drug use in these populations, pharmacotherapy is nevertheless crucial for maximizing results.},
        keywords = {Heart failure, ICD, LVAD, pharmacotherapy, evidence gaps, anticoagulation, arrhythmia management, device therapy},
        month = {September},
        }